StockData

Vanda Pharmaceuticals Inc. (VNDA) company profile

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

About Vanda Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders and other medical conditions. Its commercial product lineup includes Fanapt for schizophrenia and bipolar I disorder, Hetlioz for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome sleep disturbances, Ponvory for relapsing forms of multiple sclerosis, and Nereus for motion-induced vomiting. The company operates in a product segment and distributes its medications primarily to wholesale drug distributors and specialty pharmacies.

The company is based in Washington, D.C., where it maintains its principal executive offices. Its commercial operations center on the United States, alongside product distribution in select international markets including Canada, Israel, and European nations such as the United Kingdom. Its operations encompass four commercial-stage prescription medicines along with multiple drug candidates undergoing clinical development.

Summary of the business section of Vanda Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Vanda Pharmaceuticals Inc.
Founded
2002
Headquarters
Washington, DC
Address
2200 Pennsylvania Ave Nw, Suite 300e 20037
Phone
(202) 734-3400
Employees
533, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Washington, District of Columbia

Stock & identifiers

Ticker
VNDA
Exchange
Nasdaq
IPO date
Apr 13, 2006
Shares outstanding
60M, Oct 22, 2026
Public float
$268.70M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1347178
CUSIP
921659108
ISIN
US9216591084
FIGI
BBG000HT5MG6
Share class FIGI
BBG001SP95N5
LEI
529900AY8VOOQBKJ0O70
EIN
03-0491827

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mihael Hristos PolymeropoulosPresident and CEO, Director2,704,496
Daniel Patrick McGuireSVP, GC and Secretary109,982
Christos Vasilios Mihael PolymeropoulosSenior VP, Medical Director129,791
Scott Laverne HowellVP and Chief People Officer109,620
Joakim WijkstromSVP, Chief Marketing Officer333,469
Timothy WilliamsSVP & General Counsel377,450
Gunther BirznieksSVP, Business Development494,197
Kevin Patrick MoranSVP, CFO & Treasurer412,015
Charles Cliff DuncanDirector108,701
Richard W. DuganDirector219,054
Phaedra ChrousosDirector164,950
Anne Sempowski WardDirector160,667
Stephen Ray MitchellDirector112,846
Tage HonoreDirector135,069

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.85M$7.63M$1.44M$67$120
FY2024$3.90M$4.34M$1.35M$36$91
FY2023$3.72M$1.78M$1.36M$32$92
FY2022$4.27M$859.61K$1.51M$56$89
FY2021$6.19M$5.60M$1.96M$119$99
FY2020$2.91M$2.06M$1.15M$80$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Mihael H. Polymeropoulos, M.D.
President, Chief Executive Officer and Chairman of the Board
$965.66K$2.01M$834.33K$44.49K$3.85M-1%
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
$559.94K$557.50K$272.13K$50.10K$1.44M-1%
Gunther Birznieks
Senior Vice President, Business Development
$559.94K$557.50K$272.13K$25.91K$1.42M-1%
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
$579.60K$557.50K$281.69K$38.74K$1.46M+37%
Timothy Williams
Senior Vice President, General Counsel and Secretary
$559.94K$557.50K$272.13K$55.41K$1.44M-1%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 13, 2006
Offer price
$10.00
Securities offered
5,750,000
Gross proceeds
$57.50M
Exchange
Nasdaq
First trading day
Apr 12, 2006
First-day close
$9.68-3.2%
Lock-up ends (est.)
Oct 9, 2006

“Our common stock has been approved for quotation on the Nasdaq National Market under the symbol “VNDA.” Per share Total Initial public offering price $ 10.00 $ 57,500,000 Underwriting discounts and commissions $ 0.70 $ 4,025,000 Proceeds to us, before expenses $ 9.30 $ 53,475,000 We have granted the underwriters an option for a period of 30 days to purchase up to 862,500 additional shares of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 533 full-time employees as of December 31, 2025, compared with 368 employees as of December 31, 2024.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?